Xencor (XNCR) Other Non-Current Assets (2013 - 2026)
Xencor (XNCR) posted quarterly Other Non-Current Assets of $498000.0 for Q1 2026, up 75.35% year-over-year from $284000.0 in Q1 2025, and up 72.32% quarter-over-quarter from $289000.0 in Q4 2025.
Powered by 
Analysis
Xencor (XNCR) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Other Non-Current Assets for 14 consecutive years, with $498000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 75.35% year-over-year to $498000.0; the TTM figure through Mar 2026 stood at $498000.0 (up 75.35% YoY), while the FY2025 annual figure was $289000.0, down 41.97% from the prior year.
- Other Non-Current Assets grew to $498000.0 in Q1 2026 per XNCR's latest filing, from $289000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $648000.0 in Q4 2023 and bottomed at $284000.0 in Q1 2025.
- Historically, Other Non-Current Assets has averaged $449285.7 across 5 years, with a median of $449000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 98.17% — and 2026, when it surged 75.35%.
- Xencor's Other Non-Current Assets stood at $613000.0 in 2022, then climbed by 5.71% to $648000.0 in 2023, then slipped by 23.15% to $498000.0 in 2024, then plunged by 41.97% to $289000.0 in 2025, then surged by 72.32% to $498000.0 in 2026.
- Business Quant data shows XNCR's Other Non-Current Assets at $498000.0 in Q1 2026, $289000.0 in Q4 2025, and $288000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - | 498,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 498,000.00 |
| Mar 31, 2026 | 498,000.00 |
| Dec 31, 2025 | 498,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Dec 31, 2024 | 498,000.00 |
| Sep 30, 2024 | 498,000.00 |
| Jun 30, 2024 | 498,000.00 |
| Mar 31, 2024 | 498,000.00 |
| Dec 31, 2023 | 648,000.00 |
| Sep 30, 2023 | 378,000.00 |
| Sep 30, 2022 | 613,000.00 |
| Jun 30, 2022 | 613,000.00 |
| Mar 31, 2022 | 613,000.00 |
| Dec 31, 2021 | 653,000.00 |
| Sep 30, 2021 | 33.46 Mn |
| Jun 30, 2021 | 4.35 Mn |
| Mar 31, 2021 | 10.42 Mn |
| Dec 31, 2020 | 212,000.00 |